620
2015581226014562121176
PŘEHLEDOVÝ3675207016974156235334409485586692777867
ČLÁNEK4580207016989163260360438521
Ces36947936014570127174
Urol38937936014578115180208
2019;41267936014562121176229253
23(3):44047936014562122153211240262
194–20246927936014561114176239294353410
27.624896013356109121
Lin76889601335782142
DW,938896013373165182
Newcomb1149896013372127207255314405467
LF,1640896013357109121
Brown178989601336096155235296
MD,2113896013389162181
et231789601336097
al.243789601335883106
Evaluating2567898013156104154176233282314336394453
the304489801313997151
Four3219898013156112170201
Kallikrein3445898013159110133154176221254306328385
Panel3854898013161109166220242
of412589801315987
the423689801313997150
4Kscore4411898013158112156205260292344
for477989801313491123
Pre‑492689801316091142177
diction624104801316082130166188246304
of956104801315987
High‑grade1071104801317092151208242304335385445497
Prostate1593104801315989146186220270302353
Cancer19741048013163112170219270301
in2299104801312785
Men24121048013185139196
in2633104801312784
the2741104801313896149
Canary29181048013163113171219251302
Prostate3244104801316090147187221271303354
Active36261048013164112148170219271
Surveillance39211048013155112143196248270292313362420468519
Study.4464104801315586144203252266
Eur47541048013155110141
Urol49231048013169100157180
2017;6241198013154105153197210
72:8581198013153105123
448-45410051198013154110165199255304358
28.6241346013356111134
Tomlins7771346013355107198223248308350
SA,11461346013354119144
Day13091346013373125174
JR,1503134601334099124
Lonigro16461346013352111171196256291351
RJ,20161346013359102123
et2159134601335591
al.2269134601335378100
Urine2388134801316999121179231
TMPRSS2:ERG26391348013151136190242293341392409459513580
plus3239134801316083140179
PCA334381348013155116181235
for3697134801312481113
individualized3834134801311976135157205228287343392414435478529589
prostate4443134801316192148188222272303354
cancer4817134801314998156204254285
risk62414980131325594139
assessment.787149801315090130183223263351404462494513
Eur13241498013152107138
Urol.14861498013169100156179198
2016;17081498013154105153200217
70(1):19491498013154104132180200217
45–53.21901498013154103158209259277
29.6241646013356111130
Van7811646013361111171
Neste9791646013372127170207261
L,1263164601335579
Hendriks13681646013372127188250285311362408
RJ,18021646013359103124
Dijkstra1953164601337398124175221258293346
S,2326164601335476
et2429164601335591
al.2546164601335379101
Detection26741648013171125158209258295317374433
of3134164801315987
high-grade3248164801315981140198231293324374434487
prostate3762164801316193149189224273306357
cancer41431648013152102159208259290
using4461164801315897119176235
a47211648013153
urinary4801164801315890112170219250302
molecular6241798013190148172224274331353402433
biomarker-based1081179801316184141231280311357409440469530580620673733
risk183817980131335594139
score.2001179801314190146178230247
Eur.22721798013151106138152
Urol.2448179801316999156179197
2016;26701798013153105153199216
70(5):29111798013153103132183210226
740–748.3161179801315499154212260305360379
30.6241946013356112133
McKiernan7811946013389138196223278314375427487
J,1292194601334162
Donovan13781946013373134195255306359419
MJ,18211946013389130152
O´Neill19961946013376104175231256281306
V,2326194601336177
et2427194601335592
al.2542194601335379101
A26671948013164
novel27561948013159117165217240
urine3020194801315990113170223
exosome32681948013153101157197255345398
gene36911948013160113170224
expression39391948013153101161193245285325346404462
assay4426194801315090129180226
to4676194801313490
predict4791194801316193144205226275311
high624209801315981140197
grade845209801316092142201254
prostate1123209801316193149189224273306357
cancer1504209801314998156205256287
at1815209801315082
initial1921209801312381103136158206228
biopsy.2174209801316083141201241290304
JAMA2502209801313898184248
2016;27742098013154105153200217
2(7):3015209801315479131160177
882–889.32162098013154107158210265318370385
31.6242246013356106123
Klein771224601336087141167227
EA,10222246013354122147
Cooperberg11922246013364123184246302337400455491552
MR,17672246013389148173
Magi‑Galluzzi19642246013388141202227262336389415440499546596621
C,2609224601336488
et2721224601335591
al.2836224601335378100
A29602248013164
17-gene3049224801315397124186239297350
assay3423224801315090130180226
to3673224801313591
predict3788224801316193144205226275311
prostate4123224801316193149189224274306357
cancer4504224801314999157205256288
aggre‑48162248013150109169200251286
ssiveness624239801314181102151203261314354394
in1042239801312078
the1144239801313189142
context13072398013149105163195246294330
of1658239801315987
Gleason1766239801316992145193233291350
grade2137239801315991141200253
heterogeneity,24112398013159112145196227284344397455508530563615628
tumor3063239801313188177236268
multifocality,33522398013190147169202224253310359409431453486537550
and39232398013150108167
biopsy4112239801316083140201241290
undersampling.44232398013158116176229260301351440500523544602661680
Eur6242548013151107138
Urol.7862548013169100156179198
2014;10082548013153105153199216
66(3):12482548013153108136186211228
550–560.15002548013154102154212263315369387
32.6242696013356108131
Crawford774269601336397149228262322357418
ED,12112696013354125144
Scholz13742696013354102162221247292
MC,16862696013387150174
Kar18792696013359112147
AJ,20452696013367110131
et2195269601335590
al.230526960133527799
Cell24232698013162113135156
cycle2599269801314899146167219
progression2838269801316092148207238289328368389446503
score3361269801314189144176226
and36072698013150107165
treatment3796269801313061112159191280332389420
decisions42362698013160112161182220241298356395
in4654269801311976
prostate4750269801316092148187221270302352
cancer:624284801314999157205256287307
results955284801313384125181203236278
from1257284801312962118208
an14892848013150108
ongoing16212848013158117176234257314374
registry.2019284801313284144166205239271323336
Curr23792848013163118150182
Med25852848013186139199
Res28082848013156109149
Opin.29812848013174135157215234
2014;32392848013153105153199216
30(6):34792848013153106135185211228
1025–1031.37312848013154101150203258305352402448460
33.6242996013356109131
Wyatt7742996013393146198234272
AW,10662996013367155173
Azad12582996013367117171233
AA,15102996013367136161
Volik16902996013362118144168219
SV,19282996013355116132
et2079299601335592
al.2190299601335378101
Genomic23112998013169122180238327349397
alterations2729299801314971105155187236268290348406445
in3198299801312077
cell-free32952998013149100122144177206239290344
DNA36592998013171141203
and38822998013150108167
Enzalutamide40692998013152109153203225282316365454475534587
resistence4680299801312980120141180215265323372422
in624314801312381
castration-resistant729314801314998138173204254287309366425458491543583604643678727785817
prostate1570314801316193149189224273305356
cancer.1951314801314998156205256287301
JAMA2276314801313899184248
Oncol.25483148013174133182238261279
2016;28513148013154105153200217
2(12):3092314801315479127171197214
1598–1606.3330314801315498147200256302349403457476
34.6243296013356113136
Crawford781329601336399152231267328364426
ED,12283296013354126146
Rove13953296013359120171225
KO,16423296013359132152
Trabulsi1816329601335484137199260286329354
EJ,2192329601335397118
et2332329601335591
al.2445329601335278101
Diagnostic2567329801317194143202260319360395417466
performance30553298013160115147179237269360409467516567
of3644329801315887
PCA337533298013155117183238
to4015329801313188
detect41243298013160113147198248285
prostate4431329801316093150190225275308359
cancer4812329801314999157206258290
in624344801312382
men7303448013190145204
with9583448013180103138197
increased1180344801312281131163216265306360421
prostate1626344801316194151192228279312364
specific20153448013141101156207229257283333
antigen:23723448013150109142165225279338356
a27533448013150
prospective2827344801316194152193253308359396419470523
study3375344801314076135195245
of3644344801315988
1,9623757344801315366117172224
cases.4006344801314899140194235256
J42883448013137
Urol.43493448013169101159183203
2012;45763448013154107155201220
188(5):48203448013154101156185237265283
1726–1731.624359801315498152203262310354407455468
35.6243746013356110130
Bul7783746013360120145
M,9473746013388112
Zhu10833746013360120180
X,1287374601336286
Valdagni13973746013361111136198251312372397
R,1818374601335984
et1925374601335592
al.2040374601335379101
Active21653748013164112148170219271
surveillance2460374801314198129182234256278299348406454505
for2989374801312986118
low‑risk3132374801312381159193225248287332
prostate3488374801316193150190224274306357
cancer3869374801314999157205256288
worldwide:41813748013179137169192251329352411464482
the4687374801313492145
PRIAS48563748013156109132194246
study.624389801314176133193241254
Eur9033898013151106137
Urol10643898013169100157180
2013;12683898013153105153197213
63:15053898013154105121
597–603.16503898013153102152200257311361379
36.6244046013356112134
Ross7834046013359119162204
AE,10114046013368121144
Loeb11794046013352111167229
S,1432404601335477
Landis15334046013352106166228253296
P,1853404601335868
et1945404601335592
al.2061404601335378101
Prostate‑specific2186404801315586142182217266299350384425484538587609635662710
antigen29204048013151109140163222275332
kinetics3276404801314872129182216238286327
during36284048013160117149171229288
follow‑up3940404801313087110132190268301361420
are4385404801315081133
an45434048013150107
unreliable46754048013159117148199222243292351374427
trigger62441980131346688147207260291
for939419801312986118
intervention1081419801312381113164195248300358389411469528
in1633419801312380
a17374198013150
prostate1811419801316193150190224274306357
cancer2192419801314999157205256288
surveillance2504419801314197128181233255277299347405454504
program.3033419801316092149209240290379398
J34554198013138
Clin3517419801316385106164
Oncol37054198013174133181237260
2010;39894198013154106153200219
28:42324198013154104122
2810–2816.43784198013154105152200258305356404450469
37.6244346013356109120
San7674346013354107167
Francisco957434601335386139199248273316365424
IF,140443460133267991
Werner15174346013394146181242297333
L,1873434601335275
Regan19714346013359114176229289
MM,22834346013388176200
et2506434601335591
al.2620434601335378101
Risk2744434801315678117162
stratification2930434801314075107157189211237264312362394416474532
and34864348013150107167
validation36764348013150100122143203251283306363422
of4121434801315987
prostate4232434801316092149189223273305356
specific46124348013141100154203225251278326
an‑49614348013150108141
tigen624449801313456115168226
density8714498013160113171210232265316
as1209449801315089
independent1322449801312178138191250304362422475532564
predictor1908449801316092144204226274311367399
of2328449801315887
progression2436449801316193150210241293333373394452510
in2970449801312178
men30704498013190143201
with32924498013180102136194
low3510449801312078157
risk369144980131305291136
prostate3849449801316092149189223273305356
cancer4227449801314998156205256287
during45354498013160117149171229288
active4845449801315098134156206258
surveillance.624464801314197129182234255277299348405454505522
J11704648013138
Urol12324648013169100156179
2011;14354648013154106153194205
185:16644648013153100151166
471–476.18544648013154102151200257305353372
38.6244796013356112135
Whitson7864796013393154179215259319380
JM,11894796013344132156
Porten13724796013359117152191245306
SP,17054796013354111120
Hilton1852479601337297122158217278
JF,2153479601334498110
et2290479601335591
al.2405479601335681104
The25324798013155115168
relationship2724479801313687110158190213270329368426447507
between32584798013161115148230282336393
prostate3679479801316193149189224273306357
specific40604798013144103157207228254281330
antigen44144798013153111143165224277334
change47734798013152110158216276329
and6244948013150108167
biopsy815494801316183141201242291
progression1130494801316193149209241292332372394451510
in1664494801312380
patients17684948013161111143165218276308349
on21414948013159117
active2283494801314998134156206257
surveillance2564494801314298129182234256278299348406454505
for3093494801312986118
prostate3235494801316193150190224274306357
cancer.3616494801314999157205256288302
J39424948013138
Urol4004494801316999156179
2011;42074948013154105153194204
185:44354948013154101152167
1656–166046264948013154100151203261307354408462
39.6245096013356110129
Dall’Era7765096013373125151176199254288341
MA,11405096013389156181
Konety13445096013359118179234270325
BR,16925096013359119144
Cowan18595096013363122202254315
JE,2197509601334095117
et2337509601335592
al.2452509601335378101
Active25765098013164112148170219271
surveillance2871509801314197129182233255277299348405454505
for3400509801312886118
the3542509801313492145
management37115098013190138196245304357446500557589
of4324509801315987
prostate4435509801316193149189224273305356
cancer4815509801314999157205256288
in624524801312381
a7295248013150
contemporary8035248013149105163195246335395454486536567619
cohort.14465248013149105163222254291310
Cancer17805248013163112170219270301
2008;21055248013154105160214231
112:2360524801315495139157
2664–2670.25415248013154105159214271319369419469487
40.6245396013356113134
Barayan7785396013359112147199248301361
GA,11585396013371137162
Brimo1339539601335994119210269
F,1628539601335365
Begin17125396013359114176200260
LR,19915396013352110134
et2145539601335591
al.2255539601335378100
Factors2375539801315194142178234265306
influencing2704539801311976102128185237294343364421480
disease3204539801315981119172220259312
progression3535539801316193149208239290330369390448506
of4061539801315886
prostate4167539801316092148187221271302353
cancer4540539801314998155203254285
under48455398013158115174226257
active624554801315099135157206258
surveillance:906554801314197129182233255277299348405454505522
a14535548013149
McGill15275548013185134203225247269
University18205548013169126148197249280321342376427
Health22715548013169123171193226284
Center25795548013163114172204255286
cohort.28895548013149105164222254291310
BJU3223554801315692160
Int3407554801312381113
2014;35445548013154105153199216
114:3784554801315495141158
E99–E104.39665548013151103157214266313361416434
41.6245696013356105122
Tosoian7695696013355108150211236288349
JJ,1141569601334079100
Loeb12645696013352111167229
S,1516569601335476
Feng16155696013354107168229
Z,1867569601336184
et1973569601335592
al.2087569601335379101
Association22115698013164106146204254276324356378436494
of2729569801315887
[-2]proPSA2840569801312858104130189221277332382444
with33085698013179102135193
Biopsy3525569801315577135195235285
Reclassification38335698013156109158180229269308330356382431480513535592651
During45075698013172130161184241301
Active48315698013165112148170219271
Surveillance6245848013151108139192244266288309358416464515
for1163584801312986118
Prostate1305584801315586142182217267299350
Cancer.16795848013163112170219270301315
J20185848013138
Urol20805848013169100156179
2012;22835848013154106153198215
188:25225848013154101154172
1131–1136.2718584801315394139185234283326372427446
42.6245996013356109132
Hirama779599601337297133185276329
H,1132599601337194
Sugimoto12505996013354114175200291351387446
M,17205996013388112
Ito1856599601332662121
K,2001599601336085
et2110599601335591
al.2225599601335378101
The23505998013151111164
impact25385998013124112172222270307
of2869599801315987
baseline29815998013160110150203226247305358
[-2]proPSA‑related3363599801312960106131190222279334384446478510562585633665716777
indices4164599801312381140162210261301
on44905998013158117
the4631599801313492145
predic‑4801599801316193144205226275301
tion624614801313456114172
of820614801316594
pathological9386148013167117149207265288346407428477526549
reclassification1511614801313990140162210250290311337364412462494516574632
at2167614801315789
122806148013160
year23646148013155107155186
during25746148013167124155177235294
active28926148013157105142164213265
surveillance31816148013147104135188240262283305354412460511
for3716614801313592124
low‑risk3865614801312987165198231254293338
prostate4227614801316799155195230279312363
cancer:46146148013155105163211262293313
the4951614801314199152
Japanese624629801313886146196254307347400
multicenter10486298013190147170203225273324382414465496
study1568629801314176133193241
cohort.18336298013149105164222254291310
J21676298013138
Cancer22296298013163113170219270301
Res25546298013156109149
Clin2727629801316385106164
Oncol29156298013174133181237260
2014;32006298013153105152199216
140:34406298013153100154173
257–263.36376298013154107157206253304355373
43.6246446013356109130
Ankerst7746446013367126177230265309345
DP,11386446013373131140
Xia1298644601336287138
J,1456644601334061
Thompson15366446013355116175266328370430490
IM,20496446013323110134
Jr,220264460133407592
et2314644601335490
al.2424644601335277100
Precision2544644801315585136185207245266323381
Medicine29456448013185138198219267289346398
in3367644801311976
Active34636448013164111147168217269
Surveillance37516448013151107138191242264285307355412460511
for4285644801312582113
Prostate4418644801315585141181215264296347
Cancer:47856448013162111168217267298318
Development6246598013171125174225248306366456509567599
of1245659801315886
the1356659801313189142
Canary‑Early15206598013163112170219250302335387437468491539
Detection20816598013171124158208258294316374432
Research25356598013156109149202250281328386
Network29436598013170123156238295327373
Active33386598013164112148170219271
Surveillance36316598013151107139191243265287309357415464515
Biopsy4167659801315678136196236285
Risk4474659801315578117162
Calculator.46586598013162112134183240262311343399431445
Eur6246748013151107138
Urol7866748013169100156179
2015;9896748013154106153198213
68:12266748013154107125
1083–1088.13756748013154101155206261307354408462481
44.6246896013356115137
Mamawala7936896013388141232285364417442494
MM,13196896013388176200
Rao15436896013367120180
K,1746689601336793
Landis18626896013360114174236261304
P,2189689601336776
et22886896013363100
al.2411689601336186109
Risk2543689801316486125170
prediction27376898013169101153213235283319341399458
tool3219689801314298157180
for3423689801313794126
grade3573689801316899149209262
re‑classification3859689801314092127178200249288328350376402451501533555613671
in4554689801313189
men46756898013190143201
with49086898013180102136194
favourable‑risk624704801312979127184242273323383406459493526549588633
prostate1281704801316092149189224273305356
cancer1661704801314999157206256288
on19737048013158117
active2114704801315099135157206258
surveillance.2396704801314197129182234255277299348405454505522
BJU2942704801315692160
Int3126704801312381113
2017;32637048013154105153196210
120:3497704801315398149168
25–31.36897048013154107162211257269
45.6247196013356110131
Loeb7747196013352111167229
S.1022719601335477
Shift11197198013151108130158195
from1338719801312558115204
protocol‑based1562719801316193149181237286342365398459508548601661
to2247719801313086
personalized23537198013161114146186244303351373395438490550
medicine29237198013190143203225273294352404
in3351719801312077
active3448719801315098134156205257
surveillance:3725719801314197128181233255276298346404452503520
beginning42667198013160114174196253311332390449
of4735719801315887
a48427198013150
new49127198013159112190
era.624734801315385135154
BJU802734801315592160
Int986734801312381113
2017;11237348013153105153196209
120:1356734801315499150169
3–4.15497348013154109165183
46.6247496013356114137
N7877496013372
Mottet8857496013388149184223277313
RCN,12247496013359122193216
van14667496013353105166
den16577496013362117178
Bergh,18617496013359115150211272294
E21807496013355
Briers,2260749601336095121176211255278
et2564749601335591
al.2681749601335378101
EAU28067498013154119184
guidelines30167498013160117139198251274295353406446
on34887498013159117
prostate3632749801316193149189224273305356
cancer.40137498013151101159207258289304
Edn.43417498013153111169188
presented4556749801316092144184237295327378438
at5018749801315285
the624764801313492145
EAU7937648013151117181
Annual9987648013165123180238286308
Congress13317648013162118177236268319359399
Barcelona17547648013156106137184235257315374422
2019.22007648013154106153198214
ISBN2438764801312372125194
978-94-92671-05-9.26567648013154103154188241295329382432483533582609665717750803818